Lilly Korea’s ‘Retevmo’, a RET-targeted treatment, was set for reimbursement by the Cancer Disease Review Committee after a relapse.
Letevmo is one of the ‘life-threatening or serious treatment’ items approved through the Ministry of Food and Drug Safety’s expedited review system.
The Health Insurance Review and Assessment Service (President Kim Seon-min) deliberated on ‘the reimbursement standards for drugs used in cancer patients’ at the 9th Cancer Disease Review Committee held on the 2nd in 2022.
The item that applied for medical care benefit decision was Letevmo. Review results △Advanced or metastatic RET-mutated medullary thyroid cancer requiring systemic therapy △RET fusion-positive thyroid cancer requiring systemic therapy with previous treatment with sorafenib and/or lenvatinib △Metastatic RET fusion-positive non-small cell Salary standards have been established for all lung cancer cases.
After obtaining approval for the product from the Ministry of Food and Drug Safety in March, Letevmo was presented to the Cancer Institute meeting in May, but the salary standard has not been set. However, in November, the second attempt, the threshold was crossed.
RET gene mutations are found in approximately 2-6% of non-small cell lung cancers, and it is known that up to 50% of patients with metastatic RET fusion-positive non-small cell lung cancer will experience brain metastases over their lifetime.
According to the LIBRETTO-001 clinical study based on the approval of Retevmo, the objective response rate (ORR) was 85% in the case of no previous platinum-based chemotherapy treatment experience. It was 64%. In addition, in 10 out of 11 patients, an objective central nervous system response was confirmed.
Retvmo, whose pay standards are set in Cancer Jillsim, will be reviewed by the Drug Benefit Evaluation Committee on whether or not the pay is appropriate.
The result of the deliberation on the drug that applied for the expansion of the reimbursement standard was rejected.
For ‘TS1 Capsule + Eloxatin Injection’, an application was made to expand the reimbursement standards for advanced and metastatic or recurrent gastric cancer, and advanced or metastatic gastric cancer that cannot be operated on, but it has not been set.
The Cyprolis infusion + Dajalex infusion + dexamethasone combination tried to increase the reimbursement for the treatment of multiple myeloma that had previously received more than one treatment, but was frustrated at the threshold of cancer.
